Michael Gelband’s Theravance Biopharma TBPH Stock Holding History

Michael Gelband’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$365K	Buy	+21,473	New	+$356K	﹤0.01%	1315
2025 Q2	–	Sell	-28,437	Closed	-$254K	–	1961
2025 Q1	$254K	Buy	+28,437	New	+$265K	﹤0.01%	1263
2024 Q4	–	Sell	-38,018	Closed	-$306K	–	2047
2024 Q3	$306K	Sell	38,018 -42,937	-53%	-$372K	﹤0.01%	1354
2024 Q2	$686K	Buy	80,955 +200	+0.2%	+$1.8K	﹤0.01%	1136
2024 Q1	$724K	Buy	+80,755	New	+$748K	0.01%	1046
2023 Q4	–	Sell	-117,318	Closed	-$1.01M	–	2035
2023 Q3	$1.01M	Buy	117,318 +13,637	+13%	+$132K	0.01%	966
2023 Q2	$1.07M	Buy	+103,681	New	+$1.14M	0.01%	1075
2022 Q2	–	Sell	-53,850	Closed	-$515K	–	2435
2022 Q1	$515K	Buy	+53,850	New	+$528K	0.01%	1489
2021 Q4	–	Sell	-14,791	Closed	-$109K	–	2580
2021 Q3	$109K	Sell	14,791 -76,073	-84%	-$851K	﹤0.01%	1895
2021 Q2	$1.32M	Buy	+90,864	New	+$1.71M	0.01%	858
2020 Q4	–	Sell	-18,472	Closed	-$273K	–	2364
2020 Q3	$273K	Sell	18,472 -12,933	-41%	-$242K	0.01%	1326
2020 Q2	$659K	Buy	+31,405	New	+$807K	0.02%	943

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Michael Gelband's TBPH Position: Q2 2026 in Review

Michael Gelband opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 21,473 shares worth $365K. The stake represents ﹤0.01% of the portfolio and ranks #1315 among its holdings. This is a return to the name: Michael Gelband previously reported a position in TBPH as recently as Q1 2025.

Michael Gelband first reported a position in TBPH in Q2 2020 and has held it in 12 quarters since. The position peaked at $1.32M in Q2 2021. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Michael Gelband held 21,473 shares of Theravance Biopharma worth $365K as of Q2 2026.
Theravance Biopharma was a new Michael Gelband position in Q2 2026.
Theravance Biopharma made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1315 holding.
Michael Gelband first reported a position in Theravance Biopharma in Q2 2020 and has held it in 12 quarters since.
Michael Gelband's Theravance Biopharma position peaked at $1.32M in Q2 2021.
178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.